Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -39,728 | -161,307 | -123,503 | -86,716 | -44,635 |
| Depreciation Amortization | 351 | 1,799 | 1,431 | 1,016 | 501 |
| Accounts payable and accrued liabilities | 6,275 | 543 | -1,608 | 5,193 | 3,784 |
| Other Working Capital | -5,394 | -1,076 | -2,810 | 6,043 | -2,184 |
| Other Operating Activity | -3,101 | 6,329 | 6,305 | -2,400 | -2,381 |
| Operating Cash Flow | $-41,597 | $-153,712 | $-120,185 | $-76,864 | $-44,915 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -50,201 | 41,078 | 57,828 | 34,949 | 5,578 |
| PPE Investments | N/A | 65 | 64 | -4 | N/A |
| Other Investing Activity | 0 | -1,128 | -590 | -200 | 0 |
| Investing Cash Flow | $-50,201 | $40,015 | $57,302 | $34,745 | $5,578 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 24,700 | N/A | N/A | N/A |
| Debt Repayment | -86 | -808 | -723 | -603 | -341 |
| Common Stock Issued | 243 | 117,895 | 1,654 | 3 | 3 |
| Other Financing Activity | -258 | -619 | -506 | -463 | -76 |
| Financing Cash Flow | $-101 | $141,168 | $425 | $-1,063 | $-414 |
| Beginning Cash Position | 124,644 | 97,173 | 97,173 | 97,173 | 97,173 |
| End Cash Position | 32,745 | 124,644 | 34,715 | 53,991 | 57,422 |
| Net Cash Flow | $-91,899 | $27,471 | $-62,458 | $-43,182 | $-39,751 |
| Free Cash Flow | |||||
| Operating Cash Flow | -41,597 | -153,712 | -120,185 | -76,864 | -44,915 |
| Capital Expenditure | N/A | -5 | -6 | -4 | N/A |
| Free Cash Flow | -41,597 | -153,717 | -120,191 | -76,868 | -44,915 |